Free Trial

Pulse Biosciences Q2 2023 Earnings Report

Pulse Biosciences logo
$17.61 -0.03 (-0.17%)
As of 01/17/2025 04:00 PM Eastern

Pulse Biosciences EPS Results

Actual EPS
-$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulse Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulse Biosciences Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Pulse Biosciences Earnings Headlines

Pulse Biosciences announces Paul LaViolette as CEO
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Pulse Biosciences Appoints Co-Chairman Paul LaViolette As CEO
See More Pulse Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulse Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulse Biosciences and other key companies, straight to your email.

About Pulse Biosciences

Pulse Biosciences (NASDAQ:PLSE) operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

View Pulse Biosciences Profile

More Earnings Resources from MarketBeat